Statements (12)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:clinicalTrials |
Phase 3
|
| gptkbp:date |
FDA_approved
|
| gptkbp:dosageForm |
solution
|
| gptkbp:formulation |
injection
|
| gptkbp:hasClient |
oprelvekin
|
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO 1000
|
| gptkbp:isUsedFor |
treatment of thrombocytopenia
|
| gptkbp:mandates |
prevention of severe thrombocytopenia
|
| gptkbp:manufacturer |
gptkb:OPKO_Health,_Inc.
|
| gptkbp:marketedAs |
gptkb:United_States
|
| gptkbp:route |
subcutaneous
|